Monday, May 03, 2010 4:03:04 PM
China Pharma Holdings, Inc. to Report First Quarter 2010 Financial Results on May 11, 2010
PR Newswire - May 03 at 16:01
Company Symbols: NYSE:CPHI, AMEX:CPHI
HAIKOU CITY, China, May 3 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. (&;China Pharma&;) (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it plans to release its first quarter 2010 financial results before the market opens on Tuesday, May 11, 2010.
The Company will hold a conference call at 8:00 am ET on May 11, 2010 to discuss first quarter 2010 results. Listeners may access the call by dialing 1-866-700-7173 or 1-617-213-8838 for international callers, access code: 73484838. A webcast will also be available through CPHI&;s website at http://www.chinapharmaholdings.com. A replay of the call will be accessible through May 18, 2010 by dialing 1-888-286-8010 or 1-617-801-6888 for international callers, access code: 36265935.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company&;s cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit
http://www.chinapharmaholdings.com.
China Pharma Holdings, Inc. CCG Investor Relations
Phone: +86-898-6681-1730 (China) Lei Huang, Account Manager
Email: hps@chinapharmaholdings.com Phone: +1-646-833-3417 (New York)
Email: lei.huang@ccgir.com
Vivian Chen, Sr. Market Intelligence Exec.
Phone: +1-(646)-701-7445(New York)
Email: vivian.chen@ccgir.com
Recent CPHI News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:05:47 PM
- China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split • PR Newswire (US) • 02/23/2024 09:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/15/2024 05:15:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:05:11 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:16:44 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/26/2024 10:04:49 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/12/2024 09:05:53 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/12/2024 07:42:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:05:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:05:21 PM
- China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device • PR Newswire (US) • 11/29/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:05:58 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/07/2023 09:05:29 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/27/2023 08:06:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/19/2023 08:06:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:05:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 07:40:13 PM
- China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs • PR Newswire (US) • 08/09/2023 12:30:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM